|
|
||||||||
Article |
Department of Internal Medicine, Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado
Correspondence: Dr. Stuart Linas, University of Colorado Health Sciences Center, 660 Bannock Street, Denver, CO 80204. Phone: 303-436-5905; Fax: 303-436-7249; E-mail: stuart.linas{at}uchsc.edu
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers each reduce proteinuria and blood pressure. Several studies have compared the antiproteinuric and antihypertensive effects of combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with those of therapy with either drug class alone. This article reviews those trials as well as evidence suggesting a mechanism for the benefits observed with combination therapy.
This article has been cited by other articles:
![]() |
E. Ku, J. Park, J. Vidhun, and V. Campese The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease Arch Intern Med, June 8, 2009; 169(11): 1015 - 1018. [Full Text] [PDF] |
||||
![]() |
T. Berl Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 1 - 8. [Abstract] [PDF] |
||||
![]() |
T. Berl Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2443 - 2447. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |